Of the 30 gastrointestinal patient groups, 43% represent patient interests to regulators. They most commonly participate in HTA and reimbursement reviews (35%), while 12% focus on healthcare policy and fair medicine pricing.
43% of respondents from Gastrointestinal conditions ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Gastrointestinal conditions sub-type
30 patient groups across 5 sub-types
interactions
We work with the Ministry of Health, Singapore, and submit responses during the annual call for Patient Organisations to make submissions to the Agency for Care Effectiveness, the HTA [Health Technology Assessment] body.
We work with the Ministry of Health, Singapore and make submissions when there is an annual call for Patients' Organizations to submit to the Agency for Care Effectiveness, the HTA body.
National gastrointestinal patient group, Singapore
interactions
Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies.…
National gastrointestinal patient group, Spain
actions & advocacy
[Advocate] for greater availability of well-maintained public restroom facilities, and for the establishment of a national Inflammatory Bowel Disease (IBD) awareness day.
Pour un meilleur remboursement de nos médicaments, pour avoir davantage de toilettes publiques et bien entretenues, pour avoir une journée nationale des MICI.
Regional gastrointestinal patient group, Belgium
actions & advocacy
We strongly advocate to health authorities on matters of patient access to medicines, including drug shortages, choice of medicines, routes of administration (oral or otherwise), and transitions in prescriptions from biologics to biosimilar use.
We strongly advocate on the patient drug availability to the health authorities, should there be drug shortages, choice of medicines, drug administration (orally or other), or changes in prescriptions from biologics to biosimilar use. The above reasons all have a price tag associated with reasons behind choosing one over the other. Hence, we do our best when such changes, for example, bring either patient discomfort or affect drug efficacy. We, however, have little say on drug pricing per se, and we have never contacted regulators about pricing as a topic.
National gastrointestinal patient group, Malta
The percentages below highlight how the 17 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
8 mentions
6 mentions
1 mention
1 mention
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
actions & advocacy
6 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
3 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
